Fazirsiran sodium is an antisense rnai oligonucleotide commercialized by Arrowhead Pharmaceuticals, with a leading Phase III program in Alpha-1 Antitrypsin Deficiency (A1AD). According to Globaldata, it is involved in 6 clinical trials, of which 2 were completed, 2 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Fazirsiran sodium’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Fazirsiran sodium is expected to reach an annual total of $168 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Fazirsiran sodium Overview
ARO-AAT is under development for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD). The drug candidate is administered through subcutaneous route. It is a N-acetylgalactosamine-conjugated synthetic double-stranded oligomer specific to serpin family A member 1 gene. It is a follow-on product candidate of ARC-AAT targeting the mutant alpha-1antitrypsin (Z-AAT) protein and is developed based on RNAi platform technology.
See Also:
Arrowhead Pharmaceuticals Overview
Arrowhead Pharmaceuticals (Arrowhead) is a biotech company that develops and commercializes gene silencing therapeutics. The company utilizes RNA chemistries and TRiM platform to target and silence disease-causing genes. Its pipeline products include ARO-AAT, ARO-APOC3, ARO-ANG3, ARO-PNPLA3, GSK4532990, ARO-C3, ARO-ENaC2, ARO-MUC5AC, ARO-RAGE, ARO-MMP7, ARO-COV, ARO-DUX4, ARO-SOD1, HZN-457, JNJ-3989 and Olpasiran. Arrowhead’s therapeutic areas include hypertriglyceridemia, dyslipidemia, facioscapulohumeral muscular dystrophy, complement-mediated diseases, much-obstructive or inflammatory pulmonary conditions, idiopathic pulmonary fibrosis, liver disease, gout, chronic hepatitis B and cardiovascular disease, among others. The company operates lab facilities in San Diego, California and Madison, Wisconsin, the US. Arrowhead is headquartered in Pasadena, California, the US.
The company reported revenues of (US Dollars) US$243.2 million for the fiscal year ended September 2022 (FY2022), an increase of 75.9% over FY2021. The operating loss of the company was US$178.5 million in FY2022, compared to an operating loss of US$149 million in FY2021. The net loss of the company was US$176.1 million in FY2022, compared to a net loss of US$140.9 million in FY2021.
The company reported revenues of US$146.3 million for the second quarter ended March 2023, compared to a revenue of US$62.6 million the previous quarter.
For a complete picture of Fazirsiran sodium’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
